p27(KIP1) in human lung cancers: Differential changes in small cell and non-small cell carcinomas

Cancer Research

Volumn 58, Issue 5, 1998, Pages 1042-1047

  Yatabe, Yasushi ^a   Masuda, Akira ^a   Koshikawa, Takashi ^a   Nakamura, Shigeo ^a   Kuroishi, Tetsuo ^a   Osada, Hirotaka ^a   Takahashi, Toshitada ^a   Mitsudomi, Tetsuya ^a   Takahashi, Takashi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; MONOCLONAL ANTIBODY KI 67; PROTEIN P27; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICROTUBULE ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER INHIBITION; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG DEVELOPMENT; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG TUMOR; METABOLISM; PATHOLOGY; PRENATAL DEVELOPMENT; SMALL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADULT; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 0032008536     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Statistics and Information Department. Vital Statistics, 1994 Japan, Vol. 3, pp. 96-108. Tokyo: Ministry of Health and Welfare, 1996.
2. Minna, J. D., Nau, M. M., Chiba, I., and Ihde, D. C. Lung Cancer. In: V. T. Devita, S. Rosenberg, and S. Hellman (eds.), Principles and Practice of Oncology, pp. 591-705. Philadelphia: J. B. Lippincott Co., 1989.
3. Hunter, T., and Pines, J. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
4. 1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
5. Elledge, S. J., Winston, J., and Harper, J. W. A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Cell Biol 6 388-392, 1996.
6. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
7. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S. R., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
8. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
9. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.
10. Washimi, O., Nagatake, M., Osada, H., Ueda, R., Koshikawa, T., Seki, T., Takahashi, T., and Takahashi, T. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res., 55: 514-517, 1995.
11. KIP2 gene at 11p15.5. Oncogene, 12: 1365-1368, 1996.
12. Shiohara, M., El-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D. L., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
13. Takeuchi, S., Mori, N., Koike, M., Slater, J., Park, S., Miller, C. W., Miyoshi, I., and Koeffler, H. P. Frequent loss of heterozygosity in region of the KIP1 locus in non-small cell lung cancer: evidence for a new tumor suppressor gene on the short arm of chromosome 12. Cancer Res., 56: 738-740, 1996.
14. kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res., 55: 1211-1214, 1995.
15. Kawamata, N., Morosetti, R., Miller, C. W., Park, D., Spirin, K. S., Nakamaki, T., Takeuchi, S., Hatta, Y., Simpson, J., Wilcyznski, S., Lee, Y. Y., Bartram, C. R., and Koeffler, H. P. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res., 55: 2266-2269, 1995.
16. Masuda, A., Kondo, M., Saito, T., Yatabe, Y., Kobayashi, T., Okamoto, M., Suyama, M., Takahashi, T., and Takahashi, T. Establishment of human peripheral lung epithelial cell lines (HPL1) retaining differentiated characteristics and responsiveness to epidermal growth factor, hepatocyte growth factor, and transforming growth factor β1. Cancer Res., 57: 4898-4904, 1997.
17. Reddel, R. R., Ke, Y., Gerwin, B. I., McMenamin, M. G., Lechner, J. F., Su, R. T., Brash, D. E., Park, J. B., Rhim, J. S., and Harris, C. C. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res., 48: 1904-1909, 1988.
18. Kip1. Cell, 85: 721-732, 1996.
19. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707-720, 1996.
20. Kip1-deficient mice. Cell, 85: 733-744, 1996.
21. KIP1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
22. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
23. KIP1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
24. Bodner, S. M., Minna, J. D., Jensen, S. M., D'Amico, D., Carbone, D., Mitsudomi, T., Fedorko, J., Buchhagen, D. L., Nau, M. M., Gazdar, A. F., and Linnoila, R. I. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7: 743-749, 1992.
25. Horowitz, J. M., Yandell, D. W., Park, S-H., Canning, S., Whyte, P., Buchkovich, K., Harlow, E., Weinberg, R. A., and Dryja, T. P. Point mutational inactivation of the retinoblastoma antioncogene. Science (Washington DC), 243: 973-940, 1989.
26. Horowitz, J. M., Park, S-H., Bogenmann, E., Cheng, J-C., Yandell, D. W., Kaye, F. J., Minna, J. D., Dryja, T. P., and Weinberg, R. A. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc. Natl. Acad. Sci. USA, 87: 2775-2779, 1990.
27. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55: 1206-1210, 1995.
28. Spinn, K. S., Simpson, J. F., Takeuchi, S., Kawamata, N., Miller, C. W., and Koeffler, H. P. p27/Kip1 mutation found in breast cancer. Cancer Res., 56: 2400-2404, 1996.
29. Kip1 accumulation during the cell cycle. Science (Washington DC), 271: 1861-1864, 1996.
30. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Washington DC), 269: 682-685, 1995.
31. Kranenburg, O., Schamhorst, V., Van der Eb, A. J., and Zantema, A. Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J Cell Biol., 131: 227-234, 1995.
32. Kip1 is abrogated by c-Myc. EMBO J., 15: 6595-6604, 1996.